Last reviewed · How we verify

Serratia Complicated UTI — Treatment Landscape & Competitive Intelligence

Serratia Complicated UTI (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Serratia Complicated UTI, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Arikayce Kit AMIKACIN Bristol-Myers Squibb Aminoglycoside Antibacterial 1981-01-01
Vantobra Tobramycin Sulfate Pfizer tobramycin Taste receptor type 2 member 20 1974-01-01
Tobi tobramycin Novartis Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Nebcin Nebcin University Hospital, Lille Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Serratia Complicated UTI
  2. Bristol-Myers Squibb · 1 drug in Serratia Complicated UTI
  3. Novartis · 1 drug in Serratia Complicated UTI
  4. Pfizer · 1 drug in Serratia Complicated UTI
  5. University Hospital, Lille · 1 drug in Serratia Complicated UTI

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Serratia Complicated UTI:

Cite this brief

Drug Landscape (2026). Serratia Complicated UTI — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/serratia-complicated-uti. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing